A Basal And Clinical Reseach Ofω-3 Polyunsaturated Fatty Acids To Seal Non-alcoholic Fatty Liver Disease

Part one:Preventive Effects ofω-3 Polyunsaturated Fatty Acids from seal oil on Mice with Nonalcoholic Fatty LiverObjectives:ω-3 Polyun-saturated Fatty Acids can adjust lipid metabolism. Fatty liver is one pathology appearance of metabolism syndrome.This study aims to investigateω-3 Polyun saturated Fatty Acids to prevent non-alcoholic fatty liver desease.Methods: After 72hours exposing in the SPF condition, 30 male C57BL mice were divided into three groups randomly with 10 in each group: therapy group, model group and the normal group. The normal group fed with common diet, the model group fed with the high fat diet (Liber- Decarli liquid to make nonalcoholic liver disease, which containing 71%fat,18% protein,11% carbohydrate. The therapy group fed with the high-fat diet and seal oil 0.3ml daily. After 6 weeks, all rats were sacrificed , the blood sample and liver tissue were reserved for test. TG, TC in liver tissue and serum were tested by biochemistry method respectively. Heptic cytochrome P4502E1 (CYP2E1), peroxisome proliferator activatied receptor-α(PPAR-α) and adiponectin were detected by immunohistochemistry. The pathology of liver was observed by HE stain and sudanⅢstain .Results:1. The level of steatosis: normal group hepatocyte not seen fatty degeneration; model group hepatocyte generally occurred steatesis, which was covered with fat vacuole; steatosis was remarkably slighter in the treatment group than in model group.2. Biochemical indicator compare: serum TG and TC level of model group (1.38±0.40,4.79±0.71 respectively) were increased significantly compared with normal group(0.55±0.12,2.34±0.44)(P<0.01 respectively). Compared with model group, the treatment group (0.5±0.12,2.75±0.47)were decreased markedly(P<0.05). Liver tissue TG and TC: compared with normal group( 70.63±19.67, 54.27±33.55), the level of model group(260.19±90.78,123.7±32.15) increased significantly(P<0.01 respectively); treatment group (103.58±33.28,52.17±20.24) compared with model group were decreased markedly(P<0.05 respectively).3.Cytokine compare:(1) Adiponectin(mmol/l): model group (7.27±3.45) were decreased significantly compared with normal group (21.68±2.3) (P<0.01). Compared with model group, the treatment group (12.14±0.83) were increased markedly. (2) CYP2E1: compared with model group, the treatment group were decreased markedly(P<0.05). PPAR-α: Compared with model group, the treatment group were increased significantly(P<0.05).Part two:A trial ofω-3 Polyunsaturated Fatty Acids in treatment of patients with non-alcoholic fatty liver diseaseObjectives: This study aims to ascertain the effect and safety ofω3-PUFA on patients with Non-alcoholic liver desease.Methods: It used random, double-blind, compare method to divide into two groups with 20 in each group: therapy group, control group. They were to receive eitherω-3 polyunsaturated fatty acid capsule or placebo 4.0g daily for 6 months. Serum biochemical(TC, TG, HDL, LDL, ALT, AST, GGT) examination and liver and spleen spiral computed tomography(CT) were performed at starting and 24 week end. To analyze the safty of seal oilω3-PUFA, patient's symptom,sign ,blood routine,urine routine,ECG,BUN, Cr,uric acid, bilirubin, etc were recorded at starting and at the end of 24th week.Results:1.Comparability between two groups patient :two groups patient basic data and liver-to-spleen CT attenuation ratio had no significantly difference.2.Biochemical changes: The level of serum TG, ALT and GGT of the seal oilω3-PUFA group had significantly decrease compared with placebo group( t=2.592, 2.394, 3.065;P<0.05). The levels of TC,AST,LDL and HDL compared with placebo group had no marked change after treatment( t=1.669,0.792,1.527,-1.174;P>0.05).3.Liver-to-spleen CT attenuation ratio improvement: liver-to-spleen attenuation ratio was significantly improved after 24 weeks treatment,and in comparison with placebo group, the difference was significantly ( P<0.05). Conclusion:1.ω3-PUFA,regulate though cytokines of Adiponectin, CYP2E1 , to relieve liver steatosis , thereby achieve therapeutical effect on Non-alcoholic liver desease.2.Seal oilω3-PUFA has a positive role in improving fatty infiltration for Non-alcoholic fatty liver desease, moreover, seal oil has energetic effect on decreasing serum TG level and protecting liver function.